title: [Treatment of wet age-related macular degeneration with ranibizumab in clinical practice: results and prognostic factors].
abstract: OBJECTIVE
  To evaluate the efficacy of ranibizumab in wet age-related macular degeneration (ARMD), and to identify prognostic factors.
  
  
  METHODS
  A retrospective longitudinal study of 79 eyes treated with intravitreal Ranibizumab in our hospital due to wet ARMD, with an initial regimen of three consecutive monthly injections, followed by injections on demand based on the exploratory findings. We conducted a descriptive study of the baseline examination (n=79), and 3 (n=79), 6 (n=67) and 12 months (n=49) after starting treatment. The characteristics of the baseline examination and annual examination results were compared using univariate and multivariate analysis.
  
  
  RESULTS
  After the three initial injections, the 93.67% of patients lost fewer than 15 letters, and 19% gained 15 points or more. This result remained similar at 1 year (83.67% and 20.40%, respectively). After 1 year of treatment 40.82% had a VA ≥ 0.3 and 22'45% had a VA ≤ 0.1. We used a median of 5 injections per year. The increased AV at the beginning and the persistence of large intraretinal cysts at 3 months (P=.0013), as well as the development of fibrosis during evolution (P=.0005), are associated with visual deterioration.
  
  
  CONCLUSIONS
  The guidelines used here stabilised or improved visual acuity in most patients. The most favourable cases are those with initially lower VA or large intraretinal cysts resolved after the loading phase. The appearance of fibrosis implies a poor long-term visual prognosis.
authors.affiliation: Hospital Universitario La Princesa, Madrid, España. mara_murielh@yahoo.es
authors.forename: M A
authors.initials: MA
authors.lastname: Muriel
authors.forename: B
authors.initials: B
authors.lastname: Fatela
authors.forename: A
authors.initials: A
authors.lastname: Valdivia
authors.forename: F
authors.initials: F
authors.lastname: Clement
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D011379:Prognosis; D000069579:Ranibizumab; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab